Recent advances in the rationale design of GPER ligands

C. Rosano, R. Lappano, M. F. Santolla, M. Ponassi, A. Donadini, M. Maggiolini

Research output: Contribution to journalArticlepeer-review


G-Protein Coupled Receptor (GPCR) superfamily, which comprises approximately 900 members, is the largest family of protein targets with proven therapeutic value. Although at least 500 GPCRs have been identified as therapeutically relevant, only thirteen GPCRs have been structurally characterized in apo-form or in complex with ligands. GPCRs share relatively low sequence similarity making hard the process of homology modelling, nevertheless some successful hits have been determined. Recently, the G-proteincoupled estrogen receptor 1 (GPER, formerly known as GPR30) has attracted increasing interest due to its ability in mediating estrogen signaling in different normal and cancer tissues. In this regard, the identification of selective GPER ligands has provided valuable tools in order to differentiate the specific functions elicited by this novel estrogen receptor respect to those exerted by the classical estrogen receptors (ERs). In this review, we focus on GPER examining "in silico" docking simulations and evaluating the different binding modes of diverse natural and synthetic ligands.

Original languageEnglish
Pages (from-to)6199-6206
Number of pages8
JournalCurrent Medicinal Chemistry
Issue number36
Publication statusPublished - Dec 2012


  • "In silico" docking simulations
  • Agonists/antagonists
  • Antiestrogens
  • Atomic structures
  • Binding modes
  • Estrogens
  • GPCRs
  • GPR30/GPER
  • Homology modelling
  • Receptor
  • Small molecules ligands
  • Virtual screening

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Recent advances in the rationale design of GPER ligands'. Together they form a unique fingerprint.

Cite this